Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled trial
-
Location
-
Topic
-
Methodology
-
ReferenceOCB020-18109
Purpose of study
Purpose of study
-
Concept
-
Protocol & ERB
-
Implementation
-
Completion
-
Archived
Study timeline
-
Publication added by Petros Isaakidis
4th May 2023 -
Protocol added by Petros Isaakidis
10th February 2020Dolutegravir_TB_phase_2_protocol_V1.2._MSF_ERB_REVISED_CLEAN.DOCX87.5 KB -
ERB documentation added by Petros Isaakidis
10th February 202018109_MSFERB_Amendment_Approval_23June2019.pdf683 KB -
ERB documentation added by Petros Isaakidis
10th February 2020UCT_HREC_Protocol_amendment_approval_RADIANT-TB.pdf1.59 MB
Publications
-
Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trialGriesel, Rulan "–" F1000 Research Ltd "(2021)"
Previous study
Next study